JBCPL has its presence in the International market for over two decades.
Its operations span over 50 countries around the globe. The company exports drug intermediates, bulk drugs and formulations to USA, Europe, Africa, CIS countries, Middle East, and South East Asia. The company was quick to respond to the opportunity of a liberalized Russian economy by establishing its representative office in Moscow & Kiev in 1994.This facilitated administrative and regulatory procedure for a smooth entry in the Russian market. Unfulfilling needs in these markets gave rise to a strong sales force of 45 medical representative and 35 distributors / Importers in Russia and CIS alone. A similar activity came up with opening of representative office in Vietnam, Uganda, Tanzania & Sudan. The company has gone global with its strong marketing tie-ups in SriLanka, Malaysia, Vietnam & Myanmar to promote its specialty formulation. The company also has a technical collaboration in Austria to manufacture and market their products.

The company is geared to meet the challenges of Post-GATT ERA having a strong regulatory team, which supports the international Division and helps in formulation development, analytical testing, quality assurance and medical

REGULATORY ACHIEVEMENTS:
Success comes through achievements. So is our regulatory team who are successful in filling dossiers in more than 50 countries around the globe.

• NDDS patents granted in United States of America for controlled release formulations of Ranitidine and Tropical dental formulation of Metronidazole and Chlorhexidine for Periodontal treatment.
  
  
• Metronidazole - Approved by US FDA and Therapeutic Goods Administration (TGA), Australia.
  
  
• US Patent for novel pharmaceutical formulation of Metronidazole for dental application.
  
  
• Patents also granted in South Africa for controlled release formulations Ranitidine and Nifedipine 30 mg extended release tablets.
  
  
• Patent application submitted “Pharmaceutical composition for controlled drug delivery systems” covering new NDDS formulations of Ciprofloxacin OD and Ofloxacin OD.
  
  
• ANDA’s filled for Ciproflocaxin and Flucanozole.

With a formidable turnover of Rs. 162.29 crs it is contributing to 52% to the company’s total turnover, thus JBCPL is truly an International Marketing Company.

Company’s continuous focus on brand building has reaped rich dividends, due to which many of our brands have attained leadership status in their respective markets.

With consistent and focused promotion, JBCPL has ensured whooping growths year after year which is evident from the sales graph shown below

• Metrogyl
  
• Nicardia
  
• Metrogyl Denta
  
• Fitovit
  
• Zecuf
  
• Rantac
  

Metrogyl Denta Gel is recognized and approved by Russian Dental Association as “Gel for gums – Metrogyl Denta”.


JV's/ Strategic Alliances entered into

Spectrum Pharmaceuticals Inc (Formerly known as NeoTherapeutics Inc)

JBCPL has entered into a joint venture with Spectrum Pharmaceuticals Inc (Formerly known as NeoTherapeutics Inc), USA, a research based Company listed on NASDAQ.
A Company called NeoJB LLC has been formed in USA of which Spectrum Pharmaceuticals Inc will hold 80% and JBCPL's subsidiary called J. B. Life Science Overseas Limited will own the remainder of NeoJB. NeoJB has been formed to enable the Company to market, sell and distribute Company's various products including generic formulations and natural herbal products in USA.

JBCPL will benefit from Spectrum Pharmaceuticals Inc skill in managing clinical trials and regulatory process in the United State. JBCPL will get the opportunity to unlock the commercial value of its three registered patent in USA viz. Controlled Release Formulation of Ranitindine, pharmaceutical dental formulation and pharmaceutical formulation of topical application along with other patents which are either in the process of filing or registration. ANDA filing and marketing of generic products in USA is another focus area of NeoJB.